Leg­end signs $100M deal with No­var­tis for next CAR-T bets, fol­low­ing up on Janssen suc­cess

Leg­end Biotech, which came to the fore in cell ther­a­py when John­son & John­son took a ma­jor bet in 2017 on what would be­come Carvyk­ti, has found an­oth­er Big Phar­ma part­ner for its CAR-T pipeline. It’s go­ing with No­var­tis, the mak­er of the first FDA-ap­proved CAR-T.

No­var­tis will pay the New Jer­sey-based biotech $100 mil­lion up­front in ex­change for the ex­clu­sive glob­al li­cense to cer­tain CAR-T cell ther­a­pies that go af­ter delta-like lig­and pro­tein 3, or DLL3. The pact in­cludes Leg­end’s re­cent­ly ini­ti­at­ed Phase I of small cell lung can­cer and large cell neu­roen­docrine car­ci­no­ma can­di­date LB2102.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER